Back to Journals » Cancer Management and Research » Volume 11

Modified Glasgow prognostic score as a prognostic factor for renal cell carcinomas: a systematic review and meta-analysis

Authors Hu X, Wang Y, Yang WX, Dou WC, Shao YX, Li X

Received 15 March 2019

Accepted for publication 6 June 2019

Published 4 July 2019 Volume 2019:11 Pages 6163—6173

DOI https://doi.org/10.2147/CMAR.S208839

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Melinda Thomas

Peer reviewer comments 2

Editor who approved publication: Dr Antonella D'Anneo


Xu Hu,*,1 Yan Wang,*,1 Wei-Xiao Yang,*,1 Wei-Chao Dou,1 Yan-Xiang Shao,1 Xiang Li2

1West China School of Medicine/West China Hospital, Sichuan University, Chengdu 610041, People’s Republic of China; 2Department of Urology, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, People’s Republic of China

*These authors contributed equally to this work

Objective: The modified Glasgow prognostic score (mGPS), a combination of C-reactive protein (CRP) and albumin levels, reflects systemic inflammation and nutritional status. This score has been shown to have prognosis value for various tumors. In the present study, we evaluated the prognostic value of mGPS for patients with renal cell carcinoma (RCC).
Methods: Literature search was conducted based on PubMed, Embase, and Cochrane Central Register of Controlled Trials up to December 2018. We pooled HRs and 95% CIs to evaluate the correlation between mGPS and survival in patients with RCC.
Results: Twelve studies comprising 2,391 patients were included in the present study for quantitative synthesis. Our studies demonstrated that higher mGPS was significantly correlated to poor overall survival (HR=4.31; 95%CI, 2.78–6.68; P<0.001), cancer-specific survival (HR=5.88; 95%CI, 3.93–8.78; P<0.001), recurrence-free survival (HR=3.15; 95%CI, 2.07–4.79; P<0.001), and progression-free survival (HR=1.91; 95%CI, 1.27–2.89; P=0.002). Subgroup analyses also confirmed the overall results.
Conclusion: mGPS could serve as a predictive tool for the survival of patients with RCC. In the different subgroups, the results are also consistent with previous results. In conclusion, pretreatment higher mGPS is associated with poorer survival in patients with RCC. Further external validations are necessary to strengthen this concept.

Keywords: modified Glasgow prognostic score, renal cell carcinoma, prognosis, meta-analysis


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]